Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 3, 2013, Pages 303-310

  Wu, Wen Hui ^a   Yang, Lu ^a   Peng, Fu Hua ^a   Yao, Jing ^a   Zou, Li Ling ^a   Liu, Dong ^a,b   Jiang, Xin ^a   Li, Jue ^b   Gao, Lan ^e   Qu, Jie Ming ^b,c,d   Kawut, Steven M ^f,g   Jing, Zhi Cheng ^a  

^a TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d Shanghai Municipal Health Bureau   (China)

^e FUDAN UNIVERSITY   (China)

^f Department of Medicine ^*  (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Pulmonary arterial hypertension; Socioeconomic status; Survival

Indexed keywords

ADULT; ARTICLE; CHINA; CLINICAL FEATURE; EDUCATIONAL STATUS; FEMALE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REIMBURSEMENT; SOCIAL STATUS;

ADOLESCENT; ADULT; AGED; CHINA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84873386442     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201207-1290OC     Document Type: Article

References (51)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-117.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc., and the PulmonaryHypertension Association. J Am Coll Cardiol 2009;53:1573-1619.
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.
4. O'Callaghan DS, Savale L, Montani D, Jais X, Sitbon O, Simonneau G, Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526-538.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
6. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol 2009;6:712-722.
7. Avendano M, Kunst AE, Huisman M, Lenthe FV, Bopp M, Regidor E, Glickman M, Costa G, Spadea T, Deboosere P, et al. Socioeconomic status and ischaemic heart disease mortality in 10 Western European populations during the 1990s. Heart 2006;92:461-467.
8. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006;295:784-792.
9. Salomaa V, Niemela M, Miettinen H, Ketonen M, Immonen-Raiha P, Koskinen S, Mahonen M, Lehto S, Vuorenmaa T, Palomaki P, et al. Relationship of socioeconomic status to the incidence and prehospital, 28-day, and 1-year mortality rates of acute coronary events in the FINMONICA myocardial infarction register study. Circulation 2000; 101:1913-1918.
10. Prescott E, Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Thorax 1999;54:737-741.
11. Najera-Ortiz JC, Sanchez-Perez HJ, Ochoa-Diaz H, Arana-Cedeno M, Lezama MS, Mateo MM. Demographic, health services and socioeconomic factors associated with pulmonary tuberculosis mortality in Los Altos region of Chiapas, Mexico. Int J Epidemiol 2008;37: 786-795.
12. Wu J, Liu Y, Rao K, Sun Q, Qian J, Li Z. Education-related gender differences in health in rural china.AmJ Public Health 2004;94:1713-1716.
13. Hanibuchi T, Nakaya T, Murata C. Socio-economic status and self-rated health in East Asia: a comparison of China, Japan, South Korea and Taiwan. Eur J Public Health 2012;22:47-52.
14. Tang S, Meng Q, Chen L, Bekedam H, Evans T, Whitehead M. Tackling the challenges to health equity in China. Lancet 2008;372:1493-1501.
15. Wang LD, Ma XW. Centre for Health Statistics and Information, Ministry of Health. An analysis report of national health services survey in 2003. Beijing: Peking Union Medical University Press; 2004: p. 86.
16. Wilkens H, Grimminger F, Hoeper M, Stahler G, Ehlken B, Plesnila-Frank C, Berger K, Resch A, Ghofrani A. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010;104:902-910.
17. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-1010.
18. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a us privately insured population. Appl Health Econ Health Policy 2011;9:293-303.
19. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health 1992;82:816-820.
20. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
21. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122: 164-172.
22. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
23. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973-1998.
24. Niu S, Zhao D, Zhu J, Liu J, Liu Q, Liu J, Wang W, Smith SJ. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) project. Am Heart J 2009;157:709-715.
25. Ezeamama AE, Viali S, Tuitele J, McGarvey ST. The influence of socioeconomic factors on cardiovascular disease risk factors in the context of economic development in the Samoan archipelago. Soc Sci Med 2006; 63:2533-2545.
26. Singh RB, Beegom R, Mehta AS, Niaz MA, De AK, Mitra RK, Haque M, Verma SP, Dube GK, Siddiqui HM, et al. Social class, coronary risk factors and undernutrition, a double burden of diseases, in women during transition, in five Indian cities. Int J Cardiol 1999;69: 139-147.
27. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
28. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.
29. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:1354-1360.
30. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-1064.
31. Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, Galbraith PD, Knudtson ML. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-1497.
32. Adler NE, Boyce T, Chesney MA, Cohen S, Folkman S, Kahn RL, Syme SL. Socioeconomic status and health. The challenge of the gradient. Am Psychol 1994;49:15-24.
33. Anand S, Fan VY, Zhang J, Zhang L, Ke Y, Dong Z, Chen LC. China's human resources for health: quantity, quality, and distribution. Lancet 2008;372:1774-1781.
34. van Dis J. MSJAMA. Where we live: health care in rural vs urban America. JAMA 2002;287:108.
35. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, Yuan P, Jiang X, He J, Humbert M, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011;140:301-309.
36. Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011;183:1723-1729.
37. Jing ZC, Strange G, Zhu XY, Zhou DX, Shen JY, Gu H, Yang ZK, Pan X, Xiang MX, Yao H, et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J Heart Lung Transplant 2010;29:150-156.
38. Xu XQ, Jing ZC, Zhang JH, Wu Y, Wang Y, Jiang X,Wang ZX, Sun YG, Pu JL, Yang YJ. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertens Res 2009;32:911-915.
39. China Charity Federation: the Tracleer project [accessed 2012 May 1]. Available from: http://www.tpapchina.org/
40. National Bureau of Statistics of China. 2009 [accessed 2012 May 1]. Available from: http://www.stats.gov.cn/english/statisticaldata/yearlydata/
41. Hu S, Tang S, Liu Y, Zhao Y, Escobar ML, de Ferranti D. Reform of how health care is paid for in China: challenges and opportunities. Lancet 2008;372:1846-1853.
42. Liu Y, Rao K, Wu J, Gakidou E. China's health system performance. Lancet 2008;372:1914-1923.
43. Adler NE, Ostrove JM. Socioeconomic status and health: what we know and what we don't. Ann N Y Acad Sci 1999;896:3-15.
44. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA 1998;279:1703-1708.
45. Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A. Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II). Depress Anxiety 2008;25:506-513.
46. Lorant V, Deliege D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol 2003;157:98-112.
47. Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, Borst MM. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004;66:831-836.
48. Herrmann C, Brand-Driehorst S, Buss U, Ruger U. Effects of anxiety and depression on 5-year mortality in 5,057 patients referred for exercise testing. J Psychosom Res 2000;48:455-462.
49. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, O'Connor CM, Siegler IC, Williams RB. Depression and longterm mortality risk in patients with coronary artery disease. Am J Cardiol 1996;78:613-617.
50. Frasure-Smith N, Lesperance F, Habra M, Talajic M, Khairy P, Dorian P, Roy D. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation 2009;120:134-140.
51. National Research Council (US) Panel on Understanding Divergent Trends in Longevity in High-Income Countries; Crimmins EM, Preston SH, Cohen B, editors. Explaining divergent levels of longevity in high-income countries. Washington DC: National Academies Press (US); 2011. 9, The role of inequality [accessed 2012 Oct 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK62362/